(Q33692709)

28 July 2017

title

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy (English)

1 reference

multicenter clinical trial

28 July 2017

main subject

0 references

hypereosinophilic syndrome

1 reference

18

Andrew Wardlaw

1 reference

28 July 2017

Amy D Klion

20

0 references

Hans-Uwe Simon

object named as

Hans-Uwe Simon

16

0 references

Jean Emmanuel Kahn

object named as

Jean Emmanuel Kahn

6

0 references

Thomas B Nutman

8

object named as

Thomas B Nutman

1 reference

28 July 2017

4

Gerald J Gleich

1 reference

28 July 2017

12

Florence Roufosse

1 reference

28 July 2017

7

Kristin M Leiferman

1 reference

28 July 2017

2

Bruce S Bochner

1 reference

28 July 2017

10

Johannes Ring

1 reference

28 July 2017

11

Marc E Rothenberg

1 reference

28 July 2017

15

Dagmar Simon

1 reference

28 July 2017

Princess U Ogbogu

1

1 reference

28 July 2017

Joseph H Butterfield

3

1 reference

28 July 2017

Johannes Huss-Marp

5

1 reference

28 July 2017

Florian Pfab

9

1 reference

28 July 2017

Marie-Helene Sajous

13

1 reference

28 July 2017

Javed Sheikh

14

1 reference

28 July 2017

Miguel L Stein

17

1 reference

28 July 2017

Peter F Weller

19

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

The Journal of Allergy and Clinical Immunology

28 July 2017

published in

1 reference

28 July 2017

volume

124

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

1319-25.e3

1 reference

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

Novel approaches to therapy of hypereosinophilic syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

Lymphocytic variant hypereosinophilic syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829669

High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome

30 October 2018

1 reference

12 December 2020

Response to corticosteroids in the hypereosinophilic syndrome. Association with increased serum IgE levels

1 reference

12 December 2020

The idiopathic hypereosinophilic syndrome

1 reference

12 December 2020

Abnormal Clones of T Cells Producing Interleukin-5 in Idiopathic Eosinophilia

1 reference

12 December 2020

10.1016/J.JACI.2009.09.022

Identifiers

DOI

1 reference

28 July 2017

1 reference

28 July 2017

1 reference